Cardiomyopathy Trial, Recruiting NCT07150299 Sponsor: Medical University of Vienna Condition: Cardiomyopathy
Back to Cardiomyopathy

Cardiomyopathy Trial, Recruiting

NCT07150299
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People diagnosed with obstructive hypertrophic cardiomyopathy (a condition where the heart muscle is thickened and blocks blood flow) according to specific 2023 medical guidelines
  • People who already have a cardiac MRI scan with a special type of heart blood flow imaging (called myocardial perfusion) planned as part of their regular medical care
  • People currently being treated with the standard recommended medications for their condition
  • People willing and able to attend follow-up appointments that include scans and tests
  • People willing to sign a written consent form agreeing to take part

Who may not be able to join:

  • People who experience severe fear of enclosed spaces (claustrophobia) or have any other medical reason that makes having an MRI scan unsafe
  • People with significant narrowing or blockage of the heart's own blood vessels, or who have previously had a heart stent or bypass surgery
  • People who have experienced a cardiac arrest or a serious irregular heart rhythm in the 12 months before the screening assessment
  • People with significantly reduced kidney function (confirm with trial site)
  • People with significant liver problems, including markedly elevated liver blood test results or liver cirrhosis
  • People with a known allergy to MRI contrast dye
  • People whose thickened heart muscle is caused by a different underlying condition, such as cardiac amyloidosis or Fabry disease, rather than hypertrophic cardiomyopathy
  • Women who are currently pregnant, or women of childbearing age who wish to become pregnant
  • Women who are currently breastfeeding
  • People who are unwilling to follow the study procedures and requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
5 September 2025
Est. completion
1 May 2027

Where this trial is recruiting

🇦🇹 Austria

Primary endpoints

Correlation between myocardial perfusion reserve changes and changes in the performed distance in 6MWT.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov